C4 Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview

C4 Therapeutics

02/05/2025 15:03

C4 Therapeutics Inc CCCC.OQ CCCC.O is expected to show a rise in quarterly revenue when it reports  results on May 6 (estimated) for the period ending March 31 2025

The Watertown Massachusetts-based  company is expected to report a 46.4% increase in revenue to $4.45 million from $3.04 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for C4 Therapeutics Inc is for a loss of 45 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 4.1% in the last three months. ​

Wall Street's median 12-month price target for C4 Therapeutics Inc is $12.00​, above​ its last closing price of $1.63. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.47
-0.48
-0.49
Missed
-2.6
Sep. 30 2024
-0.36
-0.38
-0.35
Beat
7.9
Jun. 30 2024
-0.37
-0.37
-0.26
Beat
30​
Mar. 31 2024
-0.36
-0.35
-0.41
Missed
-16.7
​​Dec. 31 2023
-0.64
-0.68
-0.70
Missed
-2.6
Sep. 30 2023
-0.67
-0.66
-0.52
Beat
21.2​
Jun. 30 2023
-0.69
-0.69
-0.73
Missed
-6.1
Mar. 31 2023
-0.73
-0.75
-0.71
Beat
4.8

This summary was machine generated May 2 at 14:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)